Kadner A, Chen R H, Adams D H
Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, USA.
Eur J Cardiothorac Surg. 2000 Apr;17(4):474-81. doi: 10.1016/s1010-7940(00)00362-6.
Heterotopic heart transplantation was initially developed in the laboratory for experimental transplantation. While it was more widely utilized in the pre-cyclosporine era to provide adjunct circulatory support in combination with the native heart, associated complications as well as improved long-term graft survival have now established orthotopic transplantation as the procedure of choice. Heterotopic heart transplantation is currently reserved for highly selected patients. The technique is only performed at selected transplantation centers, and indications include significant donor recipient size mismatch or irreversible recipient pulmonary hypertension. The foreseeable introduction of clinical porcine xenotransplantation may lead to renewed interest in the technique of heterotopic heart transplantation as a bridge to potential native heart recovery or allotransplantation in selected patients.
异位心脏移植最初是在实验室中为实验性移植而开发的。在环孢素时代之前，它被更广泛地用于与自身心脏联合提供辅助循环支持，然而，相关并发症以及长期移植物存活率的提高，使得原位移植成为首选手术方式。目前，异位心脏移植仅适用于经过严格挑选的患者。该技术仅在选定的移植中心进行，其适应症包括供体与受体大小严重不匹配或受体存在不可逆的肺动脉高压。临床猪异种移植的可预见引入，可能会使人们对异位心脏移植技术重新产生兴趣，将其作为某些患者潜在的自身心脏恢复或同种异体移植的桥梁。
